About the Company
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CRBP News
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND ...
Buffett Can't Get Enough of This Stock, Plus Other Insider Buying
Warren Buffett boosts his stake in this media tracking stock again, plus a leading automaker looks to the skies.
12 Most Profitable Biotech Stocks To Invest In
As an example, consider the shares of Vincerx Pharma, Inc. (NASDAQ:VINC), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ...
American Eagle Reports Upbeat Earnings, Joins Kroger, Burlington Stores And Other Big Stocks Moving Higher On Thursday
American Eagle Outfitters posted adjusted earnings of 61 cents per share, beating market estimates of 50 cents per share. The ...
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of HighPeak Energy, Inc. (NASDAQ:HPK) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter revenue results. HighPeak Energy posted GAAP earnings ...
RAPT Therapeutics GAAP EPS of -$0.80
Net loss for the fourth quarter of 2023 was $30.9 million, compared to $23.0 million for the fourth quarter of 2022. As of December 31, 2023, the Company had cash and cash equivalents and marketable ...
Travis Kelce Says Taylor Swift Is ‘Best Thing Possible’ Following ‘Amazing’ Trip to Australia
Kelce opened up about his time with Swift in Australia during on the latest episode of his 'New Heights' podcast with brother ...
Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study ...
Loading the latest forecasts...